Signs and symptoms of COVID-19 in patients with multiple sclerosis

被引：8

作者：

Schiavetti, Irene ^{[1
]}

Carmisciano, Luca ^{[1
]}

Ponzano, Marta ^{[1
]}

Cordioli, Cinzia ^{[2
]}

Cocco, Eleonora ^{[3
,4
]}

Marfia, Girolama Alessandra ^{[5
]}

Inglese, Matilde ^{[6
,7
]}

Filippi, Massimo ^{[8
,9
,10
,11
,12
]}

Radaelli, Marta ^{[13
,14
]}

Bergamaschi, Roberto ^{[15
]}

Immovilli, Paolo ^{[16
]}

Capobianco, Marco ^{[17
]}

De Rossi, Nicola ^{[2
]}

Brichetto, Giampaolo ^{[18
]}

Scandellari, Cinzia ^{[19
]}

Cavalla, Paola ^{[20
]}

Pesci, Ilaria ^{[21
]}

Confalonieri, Paolo ^{[22
]}

Perini, Paola ^{[23
]}

Trojano, Maria ^{[24
]}

Lanzillo, Roberta ^{[25
]}

Tedeschi, Gioacchino ^{[26
]}

Comi, Giancarlo ^{[27
]}

Battaglia, Mario Alberto ^{[28
,29
]}

Patti, Francesco ^{[30
,31
]}

Salvetti, Marco ^{[32
,33
]}

Sormani, Maria Pia ^{[1
,7
]}

机构：

[1] Univ Genoa, Dept Hlth Sci, Genoa, Italy

[2] Ctr Sclerosi Multipla ASST Spedali Civili Brescia, Montichiari, Italy

[3] ATS Sardegna, Ctr Sclerosi Multipla, Cagliari, Italy

[4] Univ Cagliari, Dipartimento Sci Med & Sanita Pubbl, Cagliari, Italy

[5] Tor Vergata Univ, Dept Syst Med, Multiple Sclerosis Clin & Res Unit, Rome, Italy

[6] Univ Genoa, Dept Neurosci Rehabil Ophthalmol Genet Maternal &, Genoa, Italy

[7] IRCCS Osped Policlin San Martino, Genoa, Italy

[8] IRCCS San Raffaele Sci Inst, Neurol Unit, Milan, Italy

[9] IRCCS San Raffaele Sci Inst, Neurorehabil Unit, Milan, Italy

[10] IRCCS San Raffaele Sci Inst, Neurophysiol Unit, Milan, Italy

[11] IRCCS San Raffaele Sci Inst, Div Neurosci, Neuroimaging Res Unit, Milan, Italy

[12] Univ Vita Salute San Raffaele, Milan, Italy

[13] ASST Papa Giovanni XXIII, Dept Neurol, Bergamo, Italy

[14] ASST Papa Giovanni XXIII, Multiple Sclerosis Ctr, Bergamo, Italy

[15] IRCCS Mondino Fdn, Multiple Sclerosis Res Ctr, Pavia, Italy

[16] Osped Guglielmo Saliceto, Multiple Sclerosis Ctr, Piacenza, Italy

[17] Univ Hosp San Luigi, Reg Referral Multiple Sclerosis Ctr, Dept Neurol, Turin, Italy

[18] Italian MS Soc, AISM Rehabil Ctr, Genoa, Italy

[19] UOSI Riabilitaz Sclerosi Multipla, IRCCS Ist Sci Neurol Bologna, Bologna, Italy

[20] City Hlth & Sci Univ Hosp Turin, MS Ctr, Dept Neurosci, Turin, Italy

[21] AUSL PR, Ctr SM UOC Neurol, Fidenza, Italy

[22] Ist Nazl Neurol Carlo Besta, Neuroimmunol Dept, Multiple Sclerosis Ctr, Milan, Italy

[23] Univ Padua, Dept Neurol, Multiple Sclerosis Ctr, Padua, Italy

[24] Univ Bari, Dept Basic Med Sci Neurosci & Sense Organs, Bari, Italy

[25] Federico II Univ Naples, Naples, Italy

[26] Univ Campania, Dept Adv Med & Surg Sci, Naples, Italy

[27] Univ Vita Salute San Raffaele, Casa Cura Privata Policlin, Milan, Italy

[28] Italian Multiple Sclerosis Fdn, Res Dept, Genoa, Italy

[29] Univ Siena, Dept Life Sci, Siena, Italy

[30] Univ Catania, Dept Med & Surg Sci & Adv Technol, GF Ingrassia, Catania, Italy

[31] Univ Catania, Ctr Sclerosi Multipla, Policlin Catania, Catania, Italy

[32] Sapienza Univ Rome, Dept Neurosci Mental Hlth & Sensory Organs, Rome, Italy

[33] IRCCS Neuromed, Unit Neurol, Pozzilli, Italy

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2022年 / 29卷 / 12期

基金：

美国国家卫生研究院;

关键词：

COVID-19; demyelinating diseases; disease-modifying treatment; multiple sclerosis; neurological disorders; CORONAVIRUS DISEASE 2019; INTERFERON; ANOSMIA; MANAGEMENT; ALPHA; WAVE; 1ST; 2ND;

D O I：

10.1111/ene.15554

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Background and purpose Clinical outcomes of multiple sclerosis (MS) patients affected by coronavirus disease 2019 (COVID-19) have been thoroughly investigated, but a further analysis on main signs and symptoms and their risk factors still needs attention. The objective of this study was to group together and describe based on similarity the most common signs and symptoms of COVID-19 in MS patients and identify all factors associated with their manifestation. Method Logistic and linear regression models were run to recognize factors associated with each pooled group of symptoms and their total number. Results From March 2020 to November 2021, data were collected from 1354 MS patients with confirmed infection of COVID-19. Ageusia and anosmia was less frequent in older people (odds ratio [OR] 0.98; p = 0.005) and more in smoker patients (OR 1.39; p = 0.049). Smoke was also associated with an incremental number of symptoms (OR 1.24; p = 0.031), substance abuse (drugs or alcohol), conjunctivitis and rash (OR 5.20; p = 0.042) and the presence of at least one comorbidity with shortness of breath, tachycardia or chest pain (OR 1.24; p = 0.008). Some disease-modifying therapies were associated with greater frequencies of certain COVID-19 symptoms (association between anti-CD20 therapies and increment in the number of concomitant symptoms: OR 1.29; p = 0.05). Differences in frequencies between the three waves were found for flu-like symptoms (G1, p = 0.024), joint or muscle pain (G2, p = 0.013) and ageusia and anosmia (G5, p < 0.001). All cases should be referred to variants up to Delta. Conclusion Several factors along with the choice of specific therapeutic approaches might have a different impact on the occurrence of some COVID-19 symptoms.

引用

页码：3728 / 3736

页数：9

共 38 条

[1]

[Anonymous], BAR SCLER MULT 2021

[2] COVID-19 Among Patients With Multiple Sclerosis A Systematic Review [J].